MCKESSON EUROPE

McKesson shares reached a record high of $972.06 and are currently trading just below at $971.22. In the third quarter of fiscal 2026 the company beat expectations with adjusted EPS of $9.34 (consensus $9.16) and revenue of $106.16 billion (expectation $105.87 billion). TD Cowen raised its price target to $1,012 and reiterated its "Buy" rating, citing strong performance in Oncology & Manufacturer Solutions as well as RxTS. » Más en de.investing.com

McKesson shares rose to an all-time high of $867.90. Year-to-date performance stands at 49.54% and the stock gained 39.05% over the past year, with low volatility (beta 0.39). For Q2 F2026 McKesson reported EPS of $9.86 (expectation $9.04) on revenue of $103 billion (forecast $104.15 billion), runs aggressive share buybacks and has paid dividends for 32 years. Analysts raised price targets to $965 and $1,000; InvestingPro rates the financial health as very good and still sees slight valuation upside potential despite the rally. » Más en de.investing.com

McKesson reported adjusted EPS of $9.86 for Q2 2026, beating the consensus estimate of $9.04, while revenue of $103 billion missed expectations by about $1.15 billion. The company saw strong year-over-year growth, particularly in oncology and specialty distribution, and raised its full-year EPS guidance to $38.35–$38.85. McKesson announced share buybacks of roughly $2.5 billion; the stock rose slightly by 0.31% in after-hours trading. » Más en de.investing.com